Business
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of ...
About this update from Eupraxia Pharmaceuticals, Inc.
[{"type":"text","content":"\n \n \n \n Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prngen2{\nPADDING-RIGHT:0.17em; PADDING-LEFT:0.17em; VERTICAL-ALIGN: TOP; TEXT-ALIGN: LEFT; BORDER-TOP:black 0pt; BORDER-RIGHT:black 0pt; BORDER-BOTTOM:black 0pt; BORDER-LEFT:black 0pt\n}\n.prnml4{\nMARGIN-TOP:0em; MARGIN-RIGHT:0em; MARGIN-BOTTOM:0em; MARGIN-LEFT:0.33em !IMPORTANT\n}\n.prnbcc{\nBORDER-COLLAPSE: COLLAPSE\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n VICTORIA, BC\n \n ,\n \n \n June 5, 2024\n \n \n /CNW/ - Eupraxia Pharmaceuticals Inc. (\"Eupraxia\" or the \"Company\") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that results from its Phase 2 study of EP-104IAR for the treatment of osteoarthritis of the knee will be presented at the upcoming European Alliance of Associations for Rheumatology (\"EULAR\") European Congress of Rheumatology 2024 (the \"Meeting\"). The EULAR Meeting is being held in\n \n Vienna, Austria\n \n from\n \n June 12-15, 2024\n \n .\n \n \n \n \n \n \n \n \n Presentation Details:\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Programme No.:\n \n \n \n \n \n \n OP0274\n \n \n \n \n \n \n \n \n Presentation Title:\n \n \n \n \n \n \n \n Efficacy of a Long-Acting Fluticasone Propionate Intra-Articular Injection (EP-104IAR) in Knee Osteoarthritis: Per-Protocol Analysis of a Randomised, Double-Blind, Phase 2 Trial of EP-104IAR vs Vehicle Placebo (SPRINGBOARD)\n \n \n \n \n \n \n \n \n \n Session Type:\n \n \n \n \n \n \n Oral Abstract Presentation\n \n \n \n \n \n \n \n \n Session Title:\n \n \n \n \n \n \n New Developments in Osteoarthritis\n \n \n \n \n \n \n \n \n Session Date & Time:\n \n \n \n \n \n \n June 14, 2024, from 10:50 AM to 11:00 AM CEST\n \n \n \n \n \n \n \n The presentation will also be available on Eupraxia's website at:\n \n \n...